These preclinical studies provide biochemical evidence that the dysregulation of SIRT1-AMPK-SREBP pathway and stimulation of NLRP3 inflammasome and IL-1β production may coordinately contribute to the initiation and progression of atherosclerosis. The gene discussed is PRKAA2; the disease is atherosclerosis.